1. Home
  2. OSRH vs LSTA Comparison

OSRH vs LSTA Comparison

Compare OSRH & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

N/A

Current Price

$0.51

Market Cap

18.4M

Sector

N/A

ML Signal

N/A

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

N/A

Current Price

$5.02

Market Cap

16.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSRH
LSTA
Founded
N/A
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
16.4M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
OSRH
LSTA
Price
$0.51
$5.02
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
380.7K
56.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.98
EPS
N/A
N/A
Revenue
N/A
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
56.90
52 Week Low
$0.38
$1.81
52 Week High
$4.33
$5.05

Technical Indicators

Market Signals
Indicator
OSRH
LSTA
Relative Strength Index (RSI) 52.64 71.30
Support Level $0.45 $2.31
Resistance Level $0.74 N/A
Average True Range (ATR) 0.05 0.09
MACD 0.02 0.02
Stochastic Oscillator 62.57 95.19

Price Performance

Historical Comparison
OSRH
LSTA

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: